ZGNX News Alert Zogenix Inc (ZGNX) 1.20 12/25/2014 07:09:11

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Zogenix Inc (ZGNX) 1.20 $ZGNX

3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)

Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis
PR Newswire - Mon Dec 15, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Eli Lilly and Company (NYSE: LLY), Nektar Therapeutics (NASDAQ: NKTR), Sanofi (NYSE: SNY), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, December 12, 2014, the NASDAQ Composite ended at 4,653.60, down 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish the day at 17,280.83, and the S&P 500 closed at 2,002.33, down 1.62%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 792.98, down 1.63%, while the index has advanced 7.99% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.20 (+0.04), LLY: 70.16 (+0.42), SNY: 46.35 (+0.50), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities 2014-19: Egalet 002 to Take Over from Oxycontin and Oxycodone
M2 - Mon Dec 08, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/t568bs/the_us_chronic) has announced the addition of the "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-19)" report to their offering. The report titled The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019) provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Company Coverage - Zogenix Inc. - Egalet Corporation - NektarTheropeutics Key Topics Covered: 1. Executive summary 2. Introduction: Chronic Pain 3. The US Chronic Pain Therapy Market 4. The US Chronic Pain Therapy Market: Segment Analysis 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market For more information visit http://www.researchandmarkets.com/research/t5...us_chronic
EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04)

Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Wed Dec 03, 4:41PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25 Annual Healthcare Conference in New York, NY on December 10, 2014.
ZGNX: 1.20 (+0.04)

United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com
PRWeb - Tue Dec 02, 2:55AM CST
The report titled "The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)" provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04)

Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
GlobeNewswire - Mon Dec 01, 7:30AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, were generally safe, well-tolerated and effective in treating chronic pain for up to one year. The complete findings were published in the November 2014 issue of the Journal of Pain Research (available online here).
ZGNX: 1.20 (+0.04)

FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST

MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Zogenix to Participate in Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 3:30PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014 Healthcare Conference in New York, NY on November 18, 2014.
ZGNX: 1.20 (+0.04)

Zogenix's (ZGNX) CEO Roger Hawley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:01PM CST

ZGNX: 1.20 (+0.04)

Zogenix beats Street 3Q forecasts
Automated Insights - Thu Nov 06, 3:46PM CST
SAN DIEGO (AP) _ Zogenix Inc. (ZGNX) on Thursday reported a third-quarter loss of $12.8 million.
ZGNX: 1.20 (+0.04)

Zogenix Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:20PM CST
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET
ZGNX: 1.20 (+0.04)

Zogenix beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:16PM CST

ZGNX: 1.20 (+0.04)

Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), TTHI: 6.85 (+0.02), TEVA: 57.09 (+0.33), ITCI: 17.99 (+0.16), LLY: 70.16 (+0.42), OMER: 22.09 (+0.48)

Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.20 (+0.04), SHPG: 209.29 (+0.07), MRK: 57.46 (+0.25), PFE: 31.42 (-0.03), SNY: 46.35 (+0.50)

Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products
GlobeNewswire - Fri Oct 31, 7:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P. (Purdue) under which the two companies have exchanged waivers of regulatory exclusivity applicable to their respective single-entity, extended-release hydrocodone products. These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims.
ZGNX: 1.20 (+0.04)

Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:49PM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the third quarter ended September 30, 2014, after the market closes on Thursday November 6, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
ZGNX: 1.20 (+0.04)

Zogenix Acquires U.K.-Based Brabant Pharma
GlobeNewswire - Mon Oct 27, 6:30AM CDT
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy
ZGNX: 1.20 (+0.04)

FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT

MNK: 97.84 (-0.29), EGLT: 5.97 (+0.21), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), ABBV: 66.21 (+1.86), ALKS: 56.16 (+1.02), ACUR: 0.52 (+0.02)

Zogenix (ZGNX) Shows Strength: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:39AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as the company shares rose over 11% on the day.
LCI: 42.29 (+1.79), ZGNX: 1.20 (+0.04), SGNT: 25.58 (+0.31), HPTX: 21.91 (-0.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Microinsurance Market Expected to Surpass $11 Billion by 2034

Updated Category News Views 137

Growth Trajectory of the Global Microinsurance Market The microinsurance market is witnessing remarkable transformation as consumer demands shift towards financial inclusion, coupled with increasing awareness of the myriad advantages insurance provides. This positive trend is fueled by government initiatives aimed at regulation and expansion of microinsurance offerings,...

Continue Reading
Ormat Technologies Launches Secondary Stock Offering

Updated Category News Views 188

Ormat Technologies Launches Secondary Stock Offering Ormat Technologies, Inc. (NYSE: ORA), renowned for its innovative geothermal and renewable energy solutions, recently announced an exciting development in the investment realm—the initiation of an underwritten secondary offering. This offering encompasses a total of 3,700,000 shares of common stock on behalf of ORIX...

Continue Reading
MongoDB Executive Share Transactions Highlight Growth Potential

Updated Category News Views 132

Insights from MongoDB Executive Share Transactions Cochran Hope F, a director at MongoDB, Inc. (NASDAQ: MDB), recently made notable moves with the company's Class A Common Stock, and these transactions were disclosed in the latest SEC filings. This activity has attracted attention from investors. In September, the director sold 1,174 shares at $224.38 each, which brought...

Continue Reading
Essential Guidance for Navigating Hurricane Travel Risks

Updated Category News Views 69

Essential Guidance for Navigating Hurricane Travel Risks Hurricane season brings with it the potential for severe weather that can disrupt travel plans and lead to significant financial losses. As storms like Hurricane Helene have shown, the impact can be widespread, devastating homes and infrastructure, particularly in the southeastern regions. During these turbulent...

Continue Reading
Ascend Performance Materials Launches High-Purity Production

Updated Category News Views 279

Ascend Performance Materials Starts High-Purity Acrylonitrile Production Ascend Performance Materials has recently announced an exciting new phase in its production capabilities. The company is now producing high-purity acrylonitrile at its Chocolate Bayou facility. This advancement comes after the successful installation and commissioning of state-of-the-art purification...

Continue Reading